Journal of hepatology

(ISSN: 0168-8278)

Table of Contents

From Journal of hepatology

2021 -

  • Remaining challenges in HCV elimination. 
  • MAFLD: Now is the time to capitalize on the momentum. 
  • Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche. 
  • Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. 
  • Antiviral therapy in the palliative setting of HCC (BCLC B and C). 
  • A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. 
  • TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. 
  • Diagnosis and management of secondary causes of steatohepatitis. 
  • Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH. 
  • EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. 
  • Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. 
  • FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease. 
  • IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis? 
  • Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. 
  • Combined hepatocellular-cholangiocarcinoma: An update. 
  • End-points in clinical trials for liver cancer and their value in evidence based clinical decision making: an unresolved Gordian knot. 
  • Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry. 
  • Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and nonalcoholic fatty liver development". 
  • Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930-940]. 
  • Erratum to: "MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic-associated fatty liver and steatohepatitis (J Hepatol 2020; 73: 616-627)". 
  • Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter. 
  • STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. 
  • SARS-CoV-2 infection in patients with autoimmune hepatitis. 
  • Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion. 
  • Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. 
  • Early liver transplantation for corticosteroid non-responders in acute severe autoimmune hepatitis: the SURFASA score. 
  • Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback. 
  • Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease". 
  • NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". 
  • Reply to: "Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers". 
  • Hypertension in NAFLD: an uncontrolled burden. 
  • A pioneer in transplantation: A tribute to Professor Chris Gips (18 February 1932 - 29 July 2020). 
  • Hepatitis E virus persists in the ejaculate of chronically infected men. 
  • A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. 
  • Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. 
  • Expression of NKG2D ligands is downregulated by beta-catenin signaling and associates with HCC aggressiveness. 
  • Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease. 
  • The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD. 
  • Failure to control variceal bleeding: definition matters. 
  • Systemic inflammation and liver cirrhosis complications: driving or secondary event? How to square the circle? 
  • Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with nonalcoholic fatty liver disease. 
  • CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates. 
  • We need stronger evidence for (or against) hepatocellular carcinoma surveillance. 
  • Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients. 
  • Yet more evidence that MAFLD is more than a name change. 
  • MAFLD: A holistic view to redefining fatty liver disease. 
  • Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy. 
  • Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. 
  • MAFLD: A game changer redefining fatty liver disease for adults and children. 
  • Role of core protein mutations in the development of occult HBV infection. 
  • Reply to: "External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs". 
 
 

Journal Information